Long-term Survival among Patients with Gastrointestinal Stromal Tumors Diagnosed after Another Malignancy: A SEER Population-Based Study

2020 ◽  
Author(s):  
Chaoyong Shen ◽  
Chengshi Wang ◽  
Tao He ◽  
Zhaolun Cai ◽  
Xiaonan Yin ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Population Based ◽  
Clinicopathological Characteristics ◽  
Second Primary ◽  
Primary Malignancy ◽  
Clinicopathologic Characteristics ◽  
Term Survival ◽  
Stromal Tumors ◽  
Group A

Abstract BACKGROUND: To explore overall survival (OS) and GISTs-specific survival (GSS) among cancer survivors developing a second primary gastrointestinal stromal tumors (GISTs). METHODS: We conducted a cohort study, where patients with GISTs after another malignancy (AM-GISTs, n=851) and those with only GISTs (GISTs-1, n=7660) were identified from the Surveillance, Epidemiology, End Results registries (1988-2016). Clinicopathologic characteristics and survival were compared between the two groups. RESULTS: The most commonly diagnosed first primary malignancy was prostate cancer (27.7%), followed by breast cancer (16.2%). OS among AM-GISTs was significantly inferior to that of GISTs-1: 10-year OS was 40.3% vs. 50.0%, (p<0.001); A contrary finding was observed for GSS (10-year GSS: 68.9% vs. 61.8%, p=0.002). In the AM-GISTs group, a total of 338 patients died, of which 26.0% died of their initial cancer and 40.8% died of GISTs. Independent of demographics and clinicopathological characteristics, mortality from GISTs among AM-GISTs patients was decreased compared with their GISTs-1 counterparts (HR, 0.71; 95% CI, 0.59-0.84; p<0.001); whereas OS was inferior among AM-GISTs (HR, 1.11; 95% CI, 0.99-1.25; p=0.085). CONCLUSIONS: AM-GISTs patients have decreased risk of dying from GISTs compared with GIST-1. Although another malignancy history does not seemingly affect OS for GISTs patients, clinical treatment of such patients should be cautious.

scholarly journals Radical Versus Non-Radical Resection for Small intestinal Gastrointestinal Stromal Tumors: A Propensity Score-Matched Analysis

2021 ◽  
Author(s):  
Linlin Yin ◽  
Haihao Yan ◽  
Jue Lin ◽  
Zuhong Ji ◽  
Guozhong Ji ◽  
...  
Keyword(s):  
Propensity Score ◽  
Gastrointestinal Stromal Tumors ◽  
Radical Surgery ◽  
Radical Resection ◽  
Term Survival ◽  
Long Term Survival ◽  
Resection Group ◽  
Stromal Tumors ◽  
Small Intestinal

Abstract Surgical resection is the first choice for the treatment of small intestinal gastrointestinal stromal tumors (GISTs), but the best surgical method for small intestinal stromal tumors remains undefined. It is not clear whether there is a difference in the long-term survival of small intestinal GISTs between radical surgery and non-radical surgery. We included 877 patients with small intestinal stromal tumors who underwent surgery between 2010 and 2015 from the SEER database. They were divided into the radical resection group and the non-radical resection group. To minimized the selection bias and mixed bias in the comparison, propensity score matching (PSM) and multivariate regression analysis were carried out. In the entire cohort, 120 patients underwent radical surgery and 757 patients received non-radical resection. The 1, 3, and 5-year OS rates were 95.7%, 80.2%, and 69.6% in the radical resection group versus 94.3%, 86.8%, and 77.2% in the non-radical resection group, respectively. (p=0.069) Meanwhile, radical resection had the similar CSS rates of 1, 3 and 5-year compared with non-radical surgery. (1-year CSS rate: 97.4% vs. 98.0%, 3-year CSS rate: 86.1% vs. 93.2%, 5-year CSS rate: 81.6% vs. 88.3%; p =0.056) Besides, after adjusting for other clinical factors and PSM, the long-term OS and CSS did not significantly differ between radical surgery and non-radical surgery. Our study preliminarily found that for small intestinal GISTs, there was no significant difference in long-term survival between radical surgery and non-radical surgery.

scholarly journals Duodenal gastrointestinal stromal tumors: clinicopathological characteristics, surgery, and long-term outcome

BMC Surgery ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Chaoyong Shen ◽  
Haining Chen ◽  
Yuan Yin ◽  
Jiaju Chen ◽  
Luyin Han ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Clinicopathological Characteristics ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Stromal Tumors

scholarly journals Liver Resection for Metastases from Gastrointestinal Stromal Tumors: Does it Improve Long-Term Survival?

Chirurgia ◽  
2021 ◽  
Vol 116 (4) ◽  
pp. 438
Author(s):  
Alin Kraft ◽  
Adina Croitoru ◽  
Cristian Gheorghe ◽  
Ioana Lupescu ◽  
Mugur Grasu ◽  
...  
Keyword(s):  
Liver Resection ◽  
Gastrointestinal Stromal Tumors ◽  
Term Survival ◽  
Long Term Survival ◽  
Stromal Tumors

scholarly journals Clinicopathologic Characteristics and Treatment Outcomes of Rectal Gastrointestinal Stromal Tumors: A Retrospective Study

2021 ◽  
pp. 1-5
Author(s):  
Chujun Li ◽  
Yi Lu ◽  
Junrong Chen ◽  
Honglei Chen ◽  
Jiachen Sun ◽  
...  
Keyword(s):  
Medical Records ◽  
Gastrointestinal Stromal Tumors ◽  
Anal Verge ◽  
Clinicopathologic Characteristics ◽  
Stromal Tumors ◽  
History Information ◽  
Long Term Follow Up ◽  
Rectal Gists

Background and Study Aims: To investigate the clinicopathologic characteristics, surgical and imatinib management and long-term follow-up outcomes of the rectal gastrointestinal stromal tumors (GISTs). Patients and Methods: Consecutive patients with rectal GISTs admitted to our center (from January 2013 to June 2018) were chosen. Their history information was viewed, and the follow-up results were obtained by phone or medical records. Results: Forty-nine patients (32 males and 17 females) were identified, with a median age of 59 years, and 36 patients received surgery. Most (46 patients, 93.9%) of the tumor were located within 6 cm from the anal verge, 18 patients (36.7%) had very low or low risk, and 31 patients (63.3%) had intermediate or high risk. Four kinds of surgery approach were applied in our center: trans-abdominal (8 patients, 22.2%), trans-anal/trans-perineal (15 patients, 41.7%), trans-sacral (12 patients, 33.3%) and abdominoperineal (1 patient, 2.8%). The complication is low and the mortality related to surgery is 0%. After a median follow-up of 705 days (ranged from 48 days to 1677 days), 3 patients (8.33%) were found to have a recurrence. Conclusion: Trans-anal/trans-perineal and trans-sacral surgery were more commonly used in our study, and for now, the recurrence rate had no difference, but a longer time for follow-up is needed.

Metastatic gastroesophageal cancer and long-term survival

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4560-4560
Author(s):  
D. G. Power ◽  
M. Jhawer ◽  
J. W. Feilchenfeldt ◽  
D. P. Kelsen ◽  
M. A. Shah
Keyword(s):  
Systemic Chemotherapy ◽  
Clinicopathological Characteristics ◽  
Visceral Organ ◽  
Clinicopathologic Characteristics ◽  
Term Survival ◽  
Treatment Regimens ◽  
Poorly Differentiated ◽  
Long Term Survivors

4560 Background: Despite modest therapeutic improvements, resistance to systemic chemotherapy develops in most pts with advanced gastric/GEJ (GE) adenocarcinoma. Median OS rarely exceeds 10 mo. However, a subgroup of pts(5–10%) have substantial benefit from chemotherapy, living >2 years. We describe clinicopathological characteristics of a large cohort of long term survivors(LTS) with metastatic GE adenocarcinoma. Methods: Our institutional database of pts with GE adenocarcinoma who received chemotherapy between 1999–2008 identified 103 pts with metastatic disease (M1) surviving >2 years from M1. We evaluated clinicopathologic characteristics for correlation of LTS with chemotherapy. Results: From Jan 1999–2008, 1,140 pts with metastatic GE cancer received systemic therapy. Male:female 1.9:1 and median age 66 yrs(22–89). From the time of M1, 103 pts (9%) lived >2 yrs. Of this cohort, median follow up is 51 mo and median OS from M1 is 33 mo (24–106 mo); 44 pts remain alive (43%), 9 pts ≥5 yrs. Demographics: M:F 1.8:1, median age 61 yrs (22–84). Tumors were located at GEJ/cardia (n=52), body/fundus (n=29), antrum/pylorus (n=22), and were mainly poorly differentiated (n=61). Laurens subtype was reported in 33 cases (17=diffuse, 15=intestinal). 77 pts presented with M1 and 26 developed recurrence after resection. Sites of M1 are: peritoneum(35), single visceral organ(19), M1 lymph nodes (24), >1 site (25). 52 pts received 2–3 treatment regimens, range 1–7. Common regimens were docetaxel/fluoropyrimidine (26), cisplatin/irinotecan (21), and DCF (11); intraperitoneal chemotherapy (5). Surgery was performed in 28 pts, 26 gastrectomies (15 with occult peritoneal M1, 11 once peritoneal M1 cleared) and 2 metastatectomies; 7 pts received RT(6 to primary, 1 to M1 site). No distinct clinicopathologic correlates were identified as associated with prolonged survival with systemic chemotherapy. Conclusions: Although systemic chemotherapy has modestly improved survival in advanced GE cancers, long term control is possible. The lack of clinicopathologic correlates for LTS suggests that molecular/genomic characteristics may distinguish LTS and predict chemo-sensitivity. We are now exploring tumor and normal tissue from LTS versus matched controls (survival <1 year) for molecular/genomic correlates for LTS No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document